EHA 2021 European Hematology Association - June 9-17, 2021
Chronic Myeloid Leukemia - CML - 26th Congress of EHA -
Virtual
VIDEOS
*** coming soon***
*** coming soon***
CML PATIENT ASSOCIATIONS
EHA2021 VIRTUAL: 26th EHA Annual Congress
May 25. 2021, CML Advocates Network
EHA2021 VIRTUAL: 26th EHA Annual Congress
May 25. 2021, CML Advocates Network
Message from iCMLf
CML Highlights of EHA 2021 – Biological and clinical overview
Wednesday, June 30th at 14.00 Central European Time
Join our two experts as they discuss key aspects of the CML presentations:
CML Highlights of EHA 2021 – Biological and clinical overview
Wednesday, June 30th at 14.00 Central European Time
Join our two experts as they discuss key aspects of the CML presentations:
- Clinical overview: Professor Rüdiger Hehlmann,
Founder and Chair of the European LeukemiaNet / ELN Foundation and former Head of the Department of Medicine at the University of Mannheim (Germany) - Biological overview: Dr Ilaria Pagani, Affiliate Senior Lecturer University of Adelaide/SAHMRI (Australia)
SOME INTERESTING ABSTRACTS FOR CML
*** COVID-19 ***
COVID-19 INFECTION IN CHRONIC MYELOID LEUKEMIA AFTER 1 YEAR OF THE PANDEMIC IN ITALY. A CAMPUS CML ANALYSIS
*** TREATMENT FREE REMISSION -- TKI DISCONTINUATION ***
FINAL ANALYSIS OF A PAN EUROPEAN STOP TYROSINE KINASE INHIBITOR TRIAL IN CHRONIC MYELOID LEUKEMIA : THE EURO-SKI STUDY
LOID LEUKEMIA
*** TYROSINE KINASE INHIBITOR (TKI) ***
MITOCHONDRIAL DNA MUTATIONS ARE ASSOCIATED WITH RESPONSE TO IMATINIB IN CHRONIC MYELOID LEUKAEMIA PATIENTS
OPTIC PRIMARY ANALYSIS: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB (PON)
*** GENERAL ****
THE LOSS OF LIFE EXPECTANCY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A POPULATION-BASED STUDY IN THE NETHERLANDS, 1989-2018
LOSS OF G0/G1 SWITCH GENE 2 (G0S2) IN CML PROMOTES TKI RESISTANCE BY DEREGULATING THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN
*** COVID-19 ***
COVID-19 INFECTION IN CHRONIC MYELOID LEUKEMIA AFTER 1 YEAR OF THE PANDEMIC IN ITALY. A CAMPUS CML ANALYSIS
*** TREATMENT FREE REMISSION -- TKI DISCONTINUATION ***
FINAL ANALYSIS OF A PAN EUROPEAN STOP TYROSINE KINASE INHIBITOR TRIAL IN CHRONIC MYELOID LEUKEMIA : THE EURO-SKI STUDY
LOID LEUKEMIA
*** TYROSINE KINASE INHIBITOR (TKI) ***
MITOCHONDRIAL DNA MUTATIONS ARE ASSOCIATED WITH RESPONSE TO IMATINIB IN CHRONIC MYELOID LEUKAEMIA PATIENTS
OPTIC PRIMARY ANALYSIS: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB (PON)
*** GENERAL ****
THE LOSS OF LIFE EXPECTANCY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A POPULATION-BASED STUDY IN THE NETHERLANDS, 1989-2018
LOSS OF G0/G1 SWITCH GENE 2 (G0S2) IN CML PROMOTES TKI RESISTANCE BY DEREGULATING THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN